Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amantadine for Movement Disorders in Ataxia-Telangiectasia
NCT00950196Phase 4Completed
- Sponsor
- Sheba Medical Center
- Start
- Nov 2008
- Primary completion
- Nov 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of amantadine in ataxia-telangiectasia (AT), sponsored by Sheba Medical Center. Primary endpoint: Improvement in ataxia at 2 months. Started Nov 2008; status: completed.
02
Drugs
amantadine
03
Conditions
ataxia-telangiectasia (AT)
Beyond the preview
Go deeper on NCT00950196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00950196.